PCaCommentary #148: ACTIVE SURVEILLANCE – What’s New.

by Dr. Ed Weber | Jan 19, 2021 | PCa Commentary

Active surveillance (AS) is an increasingly recommended strategy for carefully selected men with a biopsy diagnosis of low grade, localized prostate cancer.  It involves delaying primary intervention with careful follow-up monitoring with a goal of avoiding...

PCa Commentary #147: Olaparib and Rucaparib (PARP inhibitors)

by Dr. Ed Weber | Nov 17, 2020 | PCa Commentary

PCa Commentary # 146: Radium-223 (Xofigo); A Radioisotope Treatment for Prostate Cancer Metastatic to Bone. The radiobiology of Radium-223 suggests greater effectiveness when used early in metastatic castration-resistant prostate cancer (mCRPC).

by Dr. Ed Weber | Oct 7, 2020 | PCa Commentary

In 2013 Radium-223 was FDA approved for treatment of prostate cancer patients with bone metastases on the basis of a large randomized trial, ASYMPCA, comparing the radioisotope to a placebo. In 708 heavily pretreated men, the overall median survival was extended by...

PCa Commentary # 145: PSA, PSA Dynamics, and Advances in Imaging: PSA and the PSADT (PSA doubling time) Guide the Management of Prostate Cancer.

by Dr. Ed Weber | Oct 7, 2020 | PCa Commentary

Following radical prostatectomy [and radiation therapy] for organ confined disease, approximately one-third of men will develop a biochemical relapse with a detectable PSA level.”  Quoted from “PSA Doubling Time and Absolute PSA Predict Metastases-free Survival in Men...

PCa Commentary #144: THE CHECKPOINT INHIBITORS – In Search of a Role in the Treatment of Prostate Cancer: The Current Status.

by Dr. Ed Weber | Sep 1, 2020 | PCa Commentary